Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single- and multiple-ascending-dose study of LY3473329 in healthy adults
NL-OMON54964Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of muvalaplin in hyperlipidemia and lipoprotein(a) hyperlipoproteinemia (Lp(a)) (12 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Safety and tolerability after a single oral dose and Safety and tolerability after multiple once-daily oral doses. Started Aug 2020; status: completed.
02
Drugs
muvalaplin
03
Conditions
hyperlipidemialipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on NL-OMON54964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54964.